HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of cerebral ischemia with Dextran-40 or Fluosol DA 20%.

Abstract
A cat stroke model was used to evaluate the efficacy of Dextran-40 (DEX) or Fluosol-DA 20% (FDA) in the treatment of focal cerebral ischemia. The animals were assigned randomly to one of three treatment groups: control, isovolemic hemodilution with DEX or isovolemic hemodilution with FDA. The oxidation state of cytochrome aa3 was measured in-vivo using near infrared reflectance spectrophotometry. The cerebral edema was measured by magnetic resonance imaging (MRI). The MRI edema indices for the three groups revealed that the FDA group had less edema (p less than 0.05), approaching that of non-stroke controls. The relative oxidation state of aa3 for the DEX group declined both during and after hemodilution. At the ninth hour post stroke the FDA group was better (aa3 more oxidized. p less than 0.025). Changes in blood and plasma components were reflective of the extent of hemodilution. Whole blood viscosity analysis revealed a difference (p less than 0.05) at the lower shear rates comparing DEX to FDA with FDA being higher than DEX. Two animals in each of the groups were allowed to awaken at the end of the procedure for functional assessment. These observations suggest that hemodilution with FDA following stroke significantly reduces early post-ischemic cerebral edema, improves oxidation in the peri-infarct area and appears to minimize functional deficits.
AuthorsR A Kline, W Negendank, L E McCoy
JournalBiomaterials, artificial cells, and immobilization biotechnology : official journal of the International Society for Artificial Cells and Immobilization Biotechnology (Biomater Artif Cells Immobilization Biotechnol) Vol. 20 Issue 2-4 Pg. 979-83 ( 1992) ISSN: 1055-7172 [Print] United States
PMID1382645 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Blood Substitutes
  • Dextrans
  • Drug Combinations
  • Fluorocarbons
  • Hydroxyethyl Starch Derivatives
  • glucose, glycerol, hydroxyethyl starch, perfluorodecalin, perfluorotripropylamine, pluronic F-68, salts, yolk phospholipids drug combination
Topics
  • Animals
  • Blood Substitutes (administration & dosage, therapeutic use)
  • Brain Edema (prevention & control)
  • Brain Ischemia (complications, physiopathology, therapy)
  • Cats
  • Cerebrovascular Disorders (complications, physiopathology, therapy)
  • Dextrans (therapeutic use)
  • Drug Combinations
  • Fluorocarbons (administration & dosage, therapeutic use)
  • Hemodilution
  • Hydroxyethyl Starch Derivatives

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: